Publication

Article

Generic Supplements

Generic Supplement 2011
Volume0

Amneal: Superb Quality, Award-Winning Service, and Made in the USA

Amneal Pharmaceuticals, LLC is an American manufacturer dedicated to providing the highest quality generic drugs and exceptional service to both pharmacists and the patients under their care. Celebrating almost a decade in business, Amneal now ranks as the 8th largest generics supplier in the US market based on number of prescriptions dispensed, according to IMS Health 2010 data. All products are made in the company’s five fully cGMP-compliant, state-of-the-art manufacturing plants in the metro New York area.

Diversified Products—Simple to Sophisticated

Amneal now lists over 250 products approved or filed with the FDA, including controlled substances, hormonal products, high potency formulations, soft gel capsules, liquids, nasal sprays, and oral solids. The company continues to produce more mainstream, high volume drugs in a way that maximizes quality and manufacturing efficiency. At the same time, Amneal has been aggressively and successfully developing complex and niche products with high barriers-to-entry. This gives its pipeline a very balanced mix of products and creates a diverse portfolio able to address all market segments and customer needs. In addition, company acquisitions and joint ventures are focused on next-generation, technology-driven products that will drive Amneal’s strategic expansion.

The company will enhance and further diversify its pipeline by entering new therapeutic areas and adding dosage forms such as injectables, transdermal patches, creams, and ointments. Amneal plans to introduce nearly 100 new products over the next 3 years. Extensive product information can be found in the online catalog at www.amneal.com/ products. This comprehensive resource is designed for easy pharmacist and patient access to product images, package outserts, patient medication guides, and material safety data sheets (MSDS).

Dedication to Quality

Commitment to quality—both in products and processes— infuses the entire Amneal organization. A Quality-by-Design approach builds excellence into every process. Throughout the product lifecycle, Amneal performs inspections and implements improvements from R&D, vendor selection, and manufacturing to packaging and customer support. For example, all Amneal generics feature pharmacist-defined labels designed to help reduce dispensing errors and increase efficiency in filling prescriptions.

Expanded Manufacturing Capabilities

Amneal has expanded and vertically integrated many lines to better control product quality and the supply chain. Manufacturing operations as well as R&D have grown significantly in Branchburg and Piscataway, New Jersey, and Brookhaven, New York. A major investment in higher volume manufacturing equipment has enabled the firm to ramp up production substantially. The company’s tablet volume alone has increased more than 400% in the last 2 years to more than 1.3 billion tablets per month. Efficient manufacturing practices combined with powerful global sourcing alliances allow Amneal to deliver a seamless supply of affordable, highest quality generic medicines with superior service levels and tremendous value to customers.

Exceptional Customer Service

As a result of Amneal’s relentless customer focus and delivery of superior quality generics at a fair price, the company has been recognized with 6 significant customer and industry awards in the past 2 years. The awards honor excellence across the entire organization—quality, supply, pricing, account management, customer service, leadership, innovation, and collaboration. Though this recognition is deeply gratifying, even more important is customer affirmation of Amneal’s guiding principles and ethics. Amneal team members realize success isn’t magic—it’s the result of hard work and passion for serving their valued customers. PT

For more information, visit www.amneal.com.

Indomethacin Extended-Release Capsules 75 mg

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs